Which startups have raised the most funding in the cell therapy market?
Download our beautiful pitch about the cell therapy market

In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market has attracted more than $36 billion in cumulative funding across the startups in our database, with the largest companies raising well above $1 billion each.
This ranking tracks 97 cell therapy startups and compares their cumulative funding, financing history, investors, latest rounds, and current company status.
We update this list every month so the ranking reflects new funding rounds, public offerings, acquisitions, shutdowns, and other important changes across the cell therapy market.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
A quick summary table
| Metric | Value |
| Most funded cell therapy startup | Iovance Biotherapeutics, $2.5B |
| Second most funded cell therapy startup | Sana Biotechnology, $1.8B |
| Largest cell therapy funding round | Fate Therapeutics, $460M |
| Median cell therapy startup funding | Approximately $188M |
| Share of cell therapy funding captured by the top 10 | Approximately 39.6% |
| Median time since last cell therapy funding round | Approximately 30 months |
| Cell therapy startups that raised funding in the last 12 months | 26 |
| Total cumulative cell therapy funding tracked | Approximately $36.2B |
| Cell therapy startups with at least $500M raised | 25 |
| Cell therapy startups with at least $1B raised | 10 |

This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Top startups in the cell therapy market ranked by total funding raised
Here is an updated table that ranks the top startups in the cell therapy market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the cell therapy market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Iovance Biotherapeutics | Autologous TIL cancer therapies | $2.5B | 14 | March 2026 | $98M | ATM Equity | Public-market investors | IPO | Strong |
| 2 | Sana Biotechnology | Engineered cells and gene therapies | $1.8B | 7 | May 2026 | $69M | ATM Equity | Public-market investors, TD Securities | IPO | Strong |
| 3 | Lyell Immunopharma | Next-generation CAR-T cancer therapies | $1.6B | 7 | March 2026 | $50M | Private Placement | Institutional accredited investors | IPO | Strong |
| 4 | Allogene Therapeutics | Allogeneic CAR-T cell therapies | $1.4B | 5 | April 2026 | $200M | Public Offering | Goldman Sachs, Jefferies, TD Cowen | IPO | Strong |
| 5 | Autolus Therapeutics | Programmed T-cell cancer therapies | $1.4B | 10 | February 2024 | $200M | Private Placement | BioNTech | IPO | Partial |
| 6 | Legend Biotech | CAR-T cancer therapies | $1.2B | 4 | July 2022 | $350M | Follow-on Equity | Hillhouse Capital, Public investors | IPO | Strong |
| 7 | Immatics | TCR-based cancer immunotherapies | $1.2B | 11 | August 2026 | $172M | Follow-on Public Offering | Public-market investors | IPO | Strong |
| 8 | Fate Therapeutics | Programmed cellular immunotherapies | $1.1B | 8 | January 2021 | $460M | Public Offering | Institutional investors | IPO | Partial |
| 9 | Kite Pharma | CAR-T therapies for blood cancers | $1.1B | 5 | March 2017 | $410M | Follow-on Public Offering | Jefferies, Cowen, RBC Capital Markets | Acquired | Full |
| 10 | Atara Biotherapeutics | T-cell therapies for cancer | $1.0B | 10 | December 2021 | $150M | Follow-on Equity | Institutional investors | Active | Strong |
| 11 | Mesoblast | Allogeneic mesenchymal cell medicines | $914M | 13 | January 2025 | $160M | Private Placement | Existing institutional shareholders | IPO | Partial |
| 12 | Nkarta | Engineered off-the-shelf NK cell therapies | $885M | 5 | March 2024 | $240M | Public Offering | Leerink Partners, TD Cowen, Stifel | IPO | Full |
| 13 | Adaptimmune | Engineered T-cell cancer therapies | $882M | 11 | December 2024 | $29M | ATM Equity | Public-market investors | Active | Partial |
| 14 | Century Therapeutics | iPSC-derived allogeneic cell therapies | $866M | 5 | January 2026 | $135M | Private Placement | TCGX, RA Capital, Commodore Capital | IPO | Strong |
| 15 | Arcellx | CAR-T therapies using D-Domains | $801M | 7 | December 2023 | $200M | Strategic Equity | Gilead, Kite Pharma | Acquired | Strong |
| 16 | Instil Bio | TIL-based cancer therapeutics | $749M | 4 | March 2021 | $368M | IPO | Public-market investors | IPO | Partial |
| 17 | CARsgen Therapeutics | CAR-T cancer treatments | $686M | 5 | June 2021 | $400M | IPO | Public investors | IPO | Partial |
| 18 | Cellectis | Gene-edited allogeneic cell therapies | $683M | 6 | May 2024 | $140M | Strategic Equity | AstraZeneca | IPO | Partial |
| 19 | Obsidian Therapeutics | Engineered TIL therapies for solid tumors | $675M | 4 | August 2026 | $350M | PIPE / Private Placement | Balyasny, Redmile, Eventide | IPO | Full |
| 20 | Poseida Therapeutics | Allogeneic CAR-T genetic medicines | $621M | 7 | August 2022 | $80M | Public Offering | Institutional investors | Acquired | Strong |
| 21 | TScan Therapeutics | TCR-engineered T-cell cancer therapies | $598M | 7 | December 2024 | $30M | Registered Direct | Lynx1 Capital Management | IPO | Full |
| 22 | Precision BioSciences | ARCUS gene-editing cell therapies | $557M | 13 | March 2026 | $2M | Strategic Equity | TG Therapeutics | IPO | Strong |
| 23 | Gracell Biotechnologies | Next-generation CAR-T cell therapies | $540M | 5 | August 2023 | $100M | PIPE / Private Placement | Vivo Capital, OrbiMed, RA Capital | Acquired | Strong |
| 24 | Capricor Therapeutics | Cardiac cells and exosome therapeutics | $531M | 13 | December 2025 | $172M | Follow-on Public Offering | Public-market investors, Piper Sandler, Oppenheimer | IPO | Partial |
| 25 | JW Therapeutics | CAR-T therapies for Chinese patients | $513M | 3 | November 2020 | $323M | IPO | Public-market investors | IPO | Strong |
| 26 | Gamida Cell | Stem-cell and NK-cell therapies | $475M | 16 | May 2024 | $30M | Restructuring Equity | Highbridge Capital Management | Acquired | Partial |
| 27 | Cabaletta Bio | CAR-T therapies for autoimmune disease | $453M | 6 | May 2026 | $150M | Public Offering | Bain Capital Life Sciences, Adage, Cormorant | IPO | Strong |
| 28 | Celularity | Placental-derived allogeneic cell therapies | $427M | 5 | July 2023 | $3M | Registered Direct | Healthcare-focused institutional investor | IPO | Strong |
| 29 | CARGO Therapeutics | Next-generation CAR-T therapies | $396M | 3 | May 2024 | $110M | Post-IPO Equity | Wellington Management, RTW Investments, Novo Holdings | Acquired | Full |
| 30 | Achilles Therapeutics | Personalized neoantigen T-cell therapies | $383M | 4 | March 2021 | $176M | IPO | Public-market investors | Shutdown | Full |
| 31 | Artiva Biotherapeutics | Allogeneic NK-cell therapies | $377M | 3 | July 2024 | $179M | IPO | Public-market investors | IPO | Full |
| 32 | Umoja Biopharma | In-vivo CAR-T cell therapies | $371M | 4 | January 2025 | $100M | Series C | Double Point Ventures, DCVC Bio, ARK Invest | Active | Partial |
| 33 | Sonoma Biotherapeutics | Regulatory T-cell autoimmune therapies | $365M | 3 | March 2023 | $30M | Strategic Equity | Regeneron | Active | Full |
| 34 | AvenCell Therapeutics | Switchable universal CAR-T therapies | $362M | 2 | October 2024 | $112M | Series B | Novo Holdings, F-Prime Capital, Eight Roads Ventures Japan | Active | Strong |
| 35 | Senti Biosciences | Gene-circuit engineered cell therapies | $356M | 6 | December 2025 | $12M | ATM Equity Sales | Leerink Partners | IPO | Strong |
| 36 | Adicet Bio | Gamma delta T therapies | $355M | 5 | January 2024 | $98M | Public Equity | Public investors | Active | Strong |
| 37 | Capstan Therapeutics | In-vivo RNA cell engineering | $340M | 3 | March 2024 | $175M | Series B | RA Capital, Forbion, JJDC | Acquired | Full |
| 38 | Aspen Neuroscience | Autologous neuron replacement therapies | $339M | 4 | November 2025 | $115M | Series C | OrbiMed, ARCH Venture Partners, Frazier Life Sciences | Active | Full |
| 39 | OriCell Therapeutics | CAR-T cancer immunotherapies | $325M | 5 | April 2026 | $110M | Series C / Pre-IPO | Vivo Capital, Qiming Venture Partners, Beijing Medical Health Fund | Active | Full |
| 40 | Wugen / Allotera Therapeutics | Allogeneic off-the-shelf cell therapies | $323M | 3 | August 2025 | $115M | Series C | Fidelity, RiverVest Venture Partners, Lightchain Capital | Active | Strong |
| 41 | Arsenal Biosciences | Programmable CAR-T cell therapies | $305M | 2 | September 2022 | $220M | Series B | SoftBank Vision Fund 2, Bristol Myers Squibb, Byers Capital | Active | Full |
| 42 | A2 Biotherapeutics | Logic-gated precision CAR-T therapies | $270M | 5 | January 2025 | $80M | Series C | The Column Group, Samsara BioCapital | Active | Partial |
| 43 | Acepodia | Antibody-conjugated allogeneic cell therapies | $266M | 4 | June 2023 | $100M | Series D | Digital Mobile Venture | Active | Strong |
| 44 | Kyverna Therapeutics | Autoimmune CAR-T therapies | $255M | 3 | August 2023 | $145M | Series B Extension | Bain Capital, GordonMD, Gilead | IPO | Full |
| 45 | Celyad Oncology | CAR-T immunotherapies | $250M | 7 | August 2023 | $11M | Private Placement | Fortress Investment Group, Tolefi | Active | Partial |
| 46 | BlueRock Therapeutics | iPSC regenerative cell therapies | $225M | 1 | December 2016 | $225M | Series A | Bayer, Versant Ventures | Acquired | Full |
| 47 | Quell Therapeutics | Engineered regulatory T-cell therapies | $201M | 2 | November 2021 | $156M | Series B | Jeito Capital, Ridgeback Capital, SV Health Investors | Active | Full |
| 48 | Affini-T Therapeutics | TCR therapies targeting oncogenic mutations | $193M | 2 | October 2024 | $18M | Series B Extension | Vida Ventures, Leaps by Bayer | Shutdown | Strong |
| 49 | T-knife Therapeutics | TCR-T therapies for solid tumors | $188M | 2 | August 2021 | $110M | Series B | Fidelity, EQT Life Sciences, Qatar Investment Authority | Active | Full |
| 50 | Shoreline Biosciences | iPSC-derived NK and macrophage therapies | $186M | 3 | November 2021 | $140M | Series B | Ally Bridge Group, BeiGene, Boxer Capital | Active | Full |
| 51 | Caribou Biosciences | CRISPR cell therapies | $178M | 5 | March 2021 | $115M | Series C | Farallon Capital, PFM, Ridgeback | IPO | Strong |
| 52 | GentiBio | Engineered regulatory T-cell therapies | $177M | 3 | August 2022 | Undisclosed | Strategic Equity | Bristol Myers Squibb | Active | Strong |
| 53 | Juventas Cell Therapy | CAR-T and immune cell therapies | $166M | 4 | October 2021 | $63M | Series C | CICC Capital, Oceanpine Capital, Delian Capital | Active | Partial |
| 54 | ImmPACT Bio | Engineered cancer cell therapies | $162M | 3 | January 2022 | $140M | Series B | venBio, Foresite, Decheng | Acquired | Strong |
| 55 | Vor Biopharma | Engineered hematopoietic cell therapies | $152M | 8 | March 2026 | $75M | PIPE | TCG Crossover | Active | Strong |
| 56 | Indapta Therapeutics | Potent allogeneic G-NK cell therapies | $133M | 3 | October 2025 | $51M | Series C | Vertex Ventures HC, Leaps by Bayer | Active | Strong |
| 57 | Interius BioTherapeutics | In-vivo CAR-T gene delivery | $133M | 3 | June 2024 | $51M | Series B | RA Capital, Fairmount Funds, Cormorant | Acquired | Strong |
| 58 | AbelZeta Pharma | CAR-T and TIL immunotherapies | $120M | 1 | September 2021 | $120M | Series A | AstraZeneca-CICC Fund, HSG/Sequoia China, Yunfeng Capital | Active | Strong |
| 59 | Lineage Cell Therapeutics | Allogeneic regenerative cell therapies | $118M | 7 | November 2025 | $21M | ATM / Block Equity | Janus Henderson Investors | IPO | Low |
| 60 | Curocell | Next-generation CAR-T cancer therapies | $112M | 6 | April 2026 | $3M | PIPE | BNH Investment | IPO | Strong |
| 61 | Coeptis Therapeutics | Programmable CAR-T and NK therapies | $108M | 8 | February 2025 | $6M | Series A Preferred Final Close | CJC Investment Trust | IPO | Partial |
| 62 | EXUMA Biotech | CAR cell therapies for cancers | $107M | 4 | December 2021 | $41M | Series B2 | Americo Life, existing investors | Active | Partial |
| 63 | Chimeric Therapeutics | CAR-T cancer therapies | $100M | 5 | December 2024 | $20M | Placement | Institutional investors | Active | Strong |
| 64 | Triumvira Immunologics | TAC-engineered T-cell cancer therapies | $100M | 2 | March 2022 | $45M | Series A Extension | B Capital, Leaps by Bayer, Northpond Ventures | Active | Strong |
| 65 | IASO Biotherapeutics | CAR-T cancer therapies | $100M | 2 | December 2022 | $50M | Series C | Undisclosed investors | Active | Partial |
| 66 | Bioheng Therapeutics / Imviva | Allogeneic CAR-T therapies | $100M | 3 | March 2021 | $80M | Series B | GL Ventures, Decheng Capital, Octagon Capital | Active | Strong |
| 67 | Abata Therapeutics | Treg therapies for autoimmune disease | $95M | 2 | August 2024 | Undisclosed | Strategic Equity | Bristol Myers Squibb | Active | Partial |
| 68 | Clade Therapeutics | Cloaked iPSC-derived cell therapies | $87M | 1 | November 2021 | $87M | Series A | Syncona, LifeSci Venture Partners, Bristol Myers Squibb | Acquired | Full |
| 69 | Inceptor Bio | CAR-T therapies for solid tumors | $84M | 3 | January 2025 | $21M | Series A2 | Kineticos Life Sciences | Active | Full |
| 70 | Verismo Therapeutics | KIR-CAR cancer therapies | $84M | 3 | May 2026 | $28M | Strategic Equity | HLB Innovation | Active | Partial |
| 71 | Tr1X | Allogeneic Treg and CAR-Treg therapies | $75M | 1 | January 2024 | $75M | Series A | The Column Group, NEVA SGR, Alexandria Ventures | Active | Full |
| 72 | Invectys | HLA-G CAR-T cancer immunotherapies | $68M | 7 | January 2023 | Undisclosed | Private Equity | McNair Interests, private family offices | Active | Low |
| 73 | MiNK Therapeutics | Allogeneic invariant NKT cell therapies | $60M | 3 | December 2025 | $14M | ATM / Public Equity Sales | B. Riley Securities | IPO | Strong |
| 74 | Noile-Immune Biotech | PRIME CAR-T solid-tumor therapies | $59M | 9 | June 2023 | $18M | IPO | Public Investors | IPO | Partial |
| 75 | Sernova | Cell Pouch diabetes replacement therapy | $56M | 9 | April 2026 | $3M | Private Placement | Insider/director | IPO | Partial |
| 76 | PeproMene Bio | BAFF-R CAR-T cancer therapies | $56M | 4 | June 2018 | $40M | Series B | KB Investment, private investors | Active | Partial |
| 77 | Appia Bio | Stem-cell-derived CAR-iNKT cancer therapies | $52M | 3 | May 2025 | Undisclosed | Extension | Undisclosed | Shutdown | Partial |
| 78 | Kelonia Therapeutics | In-vivo gene delivery and CAR-T | $50M | 1 | April 2022 | $50M | Series A | Alta Partners, Horizons Ventures, Venrock | Acquired | Full |
| 79 | BrainStorm Cell Therapeutics | Stem-cell neurodegenerative disease therapies | $46M | 9 | May 2026 | $0M | Private Placement | Accredited investors | IPO | Low |
| 80 | Catamaran Bio | Allogeneic CAR-NK solid-tumor therapies | $42M | 2 | November 2020 | $42M | Series A | Sofinnova Partners, Lightstone Ventures, SV Health Investors | Shutdown | Partial |
| 81 | Prescient Therapeutics | OmniCAR and oncology therapies | $40M | 8 | July 2025 | $6M | SPP + Placement | Professional investors, existing shareholders | IPO | Partial |
| 82 | TC BioPharm | Gamma delta T-cell therapies | $40M | 7 | March 2023 | $6M | Public Offering | Institutional investors | Shutdown | Strong |
| 83 | Immuneel Therapeutics | Affordable CAR-T cancer therapies | $38M | 4 | June 2026 | $10M | Series B | Singularity AMC, Rainmatter, F-Prime Capital | Active | Strong |
| 84 | ONK Therapeutics | Engineered off-the-shelf NK therapies | $36M | 3 | January 2022 | $22M | Series A | Acorn Bioventures, ALSHC, Cormorant Asset Management | Active | Strong |
| 85 | Unicar Therapy | Next-generation CAR-T cancer therapies | $31M | 5 | September 2025 | Undisclosed | Strategic Equity | Hainan Haiyao, Kinetic Medical, Minsheng Securities | Active | Low |
| 86 | AffyImmune Therapeutics | CAR-T immunotherapies | $30M | 2 | December 2022 | $30M | Series A | Healthcare investors | Active | Partial |
| 87 | Cartherics | Off-the-shelf CAR-NK cell therapies | $30M | 4 | October 2024 | $10M | Private Financing | Existing investors, new private investors | Active | Partial |
| 88 | Simnova Biotherapeutics | Off-the-shelf cancer cell therapies | $28M | 2 | March 2024 | $28M | Series A+ | Youshan Capital, Oriza Equity, PagodaTree Partners | Active | Strong |
| 89 | Leucid Bio | CAR-T therapies for solid tumors | $25M | 3 | February 2025 | $9M | Series A1 | Epidarex Capital, 2Invest | Active | Strong |
| 90 | Glycostem Therapeutics | Stem-cell-derived natural killer therapies | $19M | 3 | September 2019 | $15M | Venture Equity | E&F Healthcare, LUPUS Ventures, inno.N | Active | Partial |
| 91 | CytoMed Therapeutics | Donor-derived allogeneic cancer cell therapies | $15M | 6 | January 2026 | $0M | ATM Offering | Public investors, R.F. Lafferty | IPO | Strong |
| 92 | Elicera Therapeutics | CAR-T and oncolytic cancer therapies | $15M | 3 | June 2026 | $6M | Rights Issue | Existing shareholders, DNB Bank guarantors | IPO | Partial |
| 93 | Luminary Therapeutics | Allogeneic CAR-T cell therapies | $14M | 6 | November 2025 | $1M | Series A-II | Undisclosed investors | Active | Strong |
| 94 | Xyphos Biosciences | Engineered immune cell platforms | $10M | 1 | December 2019 | $10M | Venture Financing | Undisclosed | Acquired | Low |
| 95 | Gadeta | Gamma-delta TCR cancer immunotherapies | $8M | 2 | March 2016 | $8M | Series A | Baxalta Ventures, Medicxi Ventures, Utrecht Holdings | Acquired | Partial |
| 96 | EsoBiotec | In-vivo engineered immune-cell therapies | $6M | 3 | December 2023 | $2M | Series A | Invivo Partners, Thuja Capital, UCB Ventures | Acquired | Partial |
| 97 | Shenzhen Geno-Immune Medical Institute | CAR-T and gene-therapy research | $0M | 0 | — | Undisclosed | — | — | Active | Full |

This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Key funding trends in the cell therapy market
Insights
- The top 10 cell therapy companies have raised about $14.3B, close to 40% of all funding tracked in the database, showing how strongly capital is concentrated around a relatively small group of mature platforms.
- Twenty-five cell therapy startups have raised at least $500M each. This shows that clinical development, manufacturing, regulatory work, and commercialization can require unusually large amounts of capital before a platform reaches meaningful scale.
- Public-market access plays a major role in cell therapy financing. Iovance, Sana, Lyell, Allogene, Immatics and several other heavily funded companies continued raising equity after becoming publicly traded.
- CAR-T remains the most visible capital-intensive segment of the cell therapy market, with billion-dollar companies such as Lyell, Allogene, Legend Biotech and Kite sitting near the top of the ranking.
- Large recent rounds show that investors are still willing to make concentrated cell therapy bets. Obsidian raised $350M in August 2026, Allogene raised $200M in April 2026, and Cabaletta Bio raised $150M in May 2026.
- Cell therapy financing is not limited to oncology anymore. Cabaletta Bio, Kyverna Therapeutics, Sonoma Biotherapeutics, Quell Therapeutics, Abata Therapeutics and Tr1X illustrate growing investor interest in autoimmune cell therapies and regulatory T-cell platforms.
- Some cell therapy companies reached significant scale with very few financings. BlueRock raised $225M in a single round, Arsenal Biosciences reached $305M in two rounds, and Capstan Therapeutics accumulated $340M across three rounds.
- Substantial fundraising does not remove development risk. Achilles Therapeutics raised about $383M before shutting down, while Affini-T Therapeutics raised approximately $193M, showing how clinical and strategic setbacks can affect even well-capitalized platforms.

As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
A few word about our methodology
As you can see, we built a database that ranks startups in the cell therapy market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When cell therapy funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each cell therapy startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the cell therapy market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Related blog posts
- Cell Therapy: who are the top startups?
- Which companies are the most valued in the cell therapy market?
- How strong is fundraising in the cell therapy market right now?
- A complete list of funding deals in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- How funding activity has evolved in the cell therapy market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.